Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bampton

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Gastroenterology and Hepatology|January 3, 2013
Is narrow band imaging superior to high-definition white light endoscopy in the assessment of diminutive colorectal polyps?Rajvinder Singh, Yasser Maqbool Bhat, Prem Harichander Thurairajah, et al.
Brain, Behavior, and Immunity|July 27, 2014
Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patientsPatrick A Hughes, Melissa Moretta, Amanda Lim, et al.
Digestive Diseases and Sciences|June 10, 2022
Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel DiseaseAlex Barnes, Soong-Yuan J Ooi, Kate D Lynch, et al.
European Journal of Gastroenterology & Hepatology|May 5, 2018
Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel diseaseWebber Chan, Nicole Lynch, Peter Bampton, et al.
The American Journal of Gastroenterology|June 5, 2014
PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel diseaseRebecca L Roberts, Mary C Wallace, Margien L Seinen, et al.
Journal of Crohn'S & Colitis|March 13, 2012
Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian studyKrupa Krishnaprasad, Jane M Andrews, Ian C Lawrance, et al.
Inflammatory Bowel Diseases|January 26, 2013
Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's diseaseJames D Doecke, Lisa A Simms, Zhen Zhen Zhao, et al.
Journal of Crohn'S & Colitis|December 19, 2013
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational studyPeter R Gibson, Carolynne Vaizey, Christopher M Black, et al.
BMC Medical Genetics|August 31, 2017
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score methodGuo-Bo Chen, Sang Hong Lee, Grant W Montgomery, et al.
World Journal of Gastroenterology|September 3, 2020
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and OxfordSamba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Gastroenterology and Hepatology|January 3, 2013
Is narrow band imaging superior to high-definition white light endoscopy in the assessment of diminutive colorectal polyps?Rajvinder Singh, Yasser Maqbool Bhat, Prem Harichander Thurairajah, et al.
Brain, Behavior, and Immunity|July 27, 2014
Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patientsPatrick A Hughes, Melissa Moretta, Amanda Lim, et al.
Digestive Diseases and Sciences|June 10, 2022
Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel DiseaseAlex Barnes, Soong-Yuan J Ooi, Kate D Lynch, et al.
European Journal of Gastroenterology & Hepatology|May 5, 2018
Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel diseaseWebber Chan, Nicole Lynch, Peter Bampton, et al.
The American Journal of Gastroenterology|June 5, 2014
PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel diseaseRebecca L Roberts, Mary C Wallace, Margien L Seinen, et al.
Journal of Crohn'S & Colitis|March 13, 2012
Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian studyKrupa Krishnaprasad, Jane M Andrews, Ian C Lawrance, et al.
Inflammatory Bowel Diseases|January 26, 2013
Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's diseaseJames D Doecke, Lisa A Simms, Zhen Zhen Zhao, et al.
Journal of Crohn'S & Colitis|December 19, 2013
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational studyPeter R Gibson, Carolynne Vaizey, Christopher M Black, et al.
BMC Medical Genetics|August 31, 2017
Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score methodGuo-Bo Chen, Sang Hong Lee, Grant W Montgomery, et al.
World Journal of Gastroenterology|September 3, 2020
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and OxfordSamba Siva Reddy Pulusu, Ashish Srinivasan, Krupa Krishnaprasad, et al.
Pageof 6